Merck MRK
NYSE MRK
$145.28 -1.97 (-1.34%)
At close: Oct 23, 2026 · 4:00 PM EDT

Merck (MRK) Gains from Sales and Divestitures (2010 - 2014)

Updated

Merck's Gains from Sales and Divestitures came in at $10.81 billion for Q4 2014.

Analysis

Merck (MRK) Gains from Sales and Divestitures (2010 - 2014) Analysis & Trends

For FY2014, Merck's Gains from Sales and Divestitures was $11.21 billion.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Vertex Pharmaceuticals 132.74 Bn 104.74 Bn 2.84 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 10.81 Bn
Jun 30, 2010 443.00 Mn
API Access

Merck Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=MRK&period=max&api_key=YOUR_API_KEY